Cargando…
New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro
BACKGROUND: The valuable role of immunotherapy in treating autoimmune diseases is increasingly recognized by those involved in the research and clinical application of new biopharmaceuticals products. However, many aspects related to the mechanisms of immune-modulated therapies remain to be elucidat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862051/ https://www.ncbi.nlm.nih.gov/pubmed/27165305 http://dx.doi.org/10.1186/s12896-016-0270-0 |
_version_ | 1782431297841397760 |
---|---|
author | Pileggi, Gecilmara Salviato Clemencio, Aline Dayana Malardo, Thiago Antonini, Sonir R Bonato, Vania Luiza Deperon Rios, Wendy Martin Silva, Celio L |
author_facet | Pileggi, Gecilmara Salviato Clemencio, Aline Dayana Malardo, Thiago Antonini, Sonir R Bonato, Vania Luiza Deperon Rios, Wendy Martin Silva, Celio L |
author_sort | Pileggi, Gecilmara Salviato |
collection | PubMed |
description | BACKGROUND: The valuable role of immunotherapy in treating autoimmune diseases is increasingly recognized by those involved in the research and clinical application of new biopharmaceuticals products. However, many aspects related to the mechanisms of immune-modulated therapies remain to be elucidated in order to explore fully the emerging opportunities. The non-obese diabetic NOD mouse develops insulin-dependent diabetes mellitus spontaneously as a consequence of an autoimmune process in the presence of pathogenic CD4(+) T cells that typically exhibit Th17 cell phenotypes. The change of a Th17 phenotype into a pattern of regulatory T cells (Treg) is extremely important in controlling autoimmune diseases. Heat shock proteins (HSPs) are stress-induced proteins with immunoregulatory properties. In the current study, the capacity of Hsp65 and Hsp70 mycobacterial HSPs and a constructed DNA encoded Hsp65 (DNAhsp65) to transform the pattern of the immune response from Th17 into Treg cells has been studied in vitro using co-cultures of antigen presenting cells (APCs) and T cells in NOD mice. RESULTS: Cells harvested from NOD mice and cultured for 48 h (without immunoregulatory compounds) presented with Th1/Th17 patterns and secretions of IL-6, IFN-γ, IL-10 and IL-17 cytokines. The cultured cells from the non-diabetic BALB/C mice exhibited a Th1 pattern and the production of IL 6 and IFN-γ secretions. An up-regulation was observed in the supernatants from the co-cultures of NOD cells that were stimulated with DNAhsp65, Hsp65 or Hsp70 through increased levels of IL-10 secretion and the suppression of IL-6, IFN-γ and IL-17 production. In addition, immunoregulation was demonstrated through IL-17 suppression in the co-culture stimulated by the specific insulin antigen. Moreover, an increase of immunoregulatory compounds were observed in the co-culture through the expression of CD11b(+)CD86(+) activation markers on APCs, as well as the frequency of Treg cells expressing CD4(+)CD3(+) and CD4(+)CD25(hi). CONCLUSIONS: The in vitro observation of Th17 cells differentiating into Tregs in NOD mice could raise the hypothesis that the immune regulatory activity of HSPs could be an efficient strategy for diabetes prevention and treatment. |
format | Online Article Text |
id | pubmed-4862051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48620512016-05-11 New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro Pileggi, Gecilmara Salviato Clemencio, Aline Dayana Malardo, Thiago Antonini, Sonir R Bonato, Vania Luiza Deperon Rios, Wendy Martin Silva, Celio L BMC Biotechnol Research Article BACKGROUND: The valuable role of immunotherapy in treating autoimmune diseases is increasingly recognized by those involved in the research and clinical application of new biopharmaceuticals products. However, many aspects related to the mechanisms of immune-modulated therapies remain to be elucidated in order to explore fully the emerging opportunities. The non-obese diabetic NOD mouse develops insulin-dependent diabetes mellitus spontaneously as a consequence of an autoimmune process in the presence of pathogenic CD4(+) T cells that typically exhibit Th17 cell phenotypes. The change of a Th17 phenotype into a pattern of regulatory T cells (Treg) is extremely important in controlling autoimmune diseases. Heat shock proteins (HSPs) are stress-induced proteins with immunoregulatory properties. In the current study, the capacity of Hsp65 and Hsp70 mycobacterial HSPs and a constructed DNA encoded Hsp65 (DNAhsp65) to transform the pattern of the immune response from Th17 into Treg cells has been studied in vitro using co-cultures of antigen presenting cells (APCs) and T cells in NOD mice. RESULTS: Cells harvested from NOD mice and cultured for 48 h (without immunoregulatory compounds) presented with Th1/Th17 patterns and secretions of IL-6, IFN-γ, IL-10 and IL-17 cytokines. The cultured cells from the non-diabetic BALB/C mice exhibited a Th1 pattern and the production of IL 6 and IFN-γ secretions. An up-regulation was observed in the supernatants from the co-cultures of NOD cells that were stimulated with DNAhsp65, Hsp65 or Hsp70 through increased levels of IL-10 secretion and the suppression of IL-6, IFN-γ and IL-17 production. In addition, immunoregulation was demonstrated through IL-17 suppression in the co-culture stimulated by the specific insulin antigen. Moreover, an increase of immunoregulatory compounds were observed in the co-culture through the expression of CD11b(+)CD86(+) activation markers on APCs, as well as the frequency of Treg cells expressing CD4(+)CD3(+) and CD4(+)CD25(hi). CONCLUSIONS: The in vitro observation of Th17 cells differentiating into Tregs in NOD mice could raise the hypothesis that the immune regulatory activity of HSPs could be an efficient strategy for diabetes prevention and treatment. BioMed Central 2016-05-10 /pmc/articles/PMC4862051/ /pubmed/27165305 http://dx.doi.org/10.1186/s12896-016-0270-0 Text en © Pileggi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Pileggi, Gecilmara Salviato Clemencio, Aline Dayana Malardo, Thiago Antonini, Sonir R Bonato, Vania Luiza Deperon Rios, Wendy Martin Silva, Celio L New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
title | New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
title_full | New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
title_fullStr | New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
title_full_unstemmed | New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
title_short | New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
title_sort | new strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862051/ https://www.ncbi.nlm.nih.gov/pubmed/27165305 http://dx.doi.org/10.1186/s12896-016-0270-0 |
work_keys_str_mv | AT pileggigecilmarasalviato newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro AT clemencioalinedayana newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro AT malardothiago newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro AT antoninisonirr newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro AT bonatovanialuizadeperon newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro AT rioswendymartin newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro AT silvaceliol newstrategyfortestingefficacyofimmunotherapeuticcompoundsfordiabetesinvitro |